Summit Therapeutics (SMMT) Revenue (2017 - 2022)

Summit Therapeutics (SMMT) has 6 years of Revenue data on file, last reported at $220000.0 in Q3 2022.

• Quarterly Revenue fell 83.19% year-over-year to $220000.0 in Q3 2022, while the trailing twelve-month figure through Jun 2023 was $220000.0 (down 89.24% YoY) and the FY2022 annual result came in at $705000.0, down 61.03% from the prior year.
• Revenue retreated to $220000.0 in Q3 2022, from $235000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $50.6 million in Q3 2018 to a low of -$53.9 million in Q4 2019.
• A 5-year average of $584535.3 and a median of $227500.0 in 2022 frame the typical range for Revenue.
• Annual changes were most pronounced in 2018 — Revenue soared 725.33% — and 2019, when it slumped 99.68%.
• Tracing SMMT's Revenue over 5 years: stood at $876531.1 in 2018, then plunged by 6249.55% to -$53.9 million in 2019, then jumped by 100.34% to $185000.0 in 2020, then soared by 35.68% to $251000.0 in 2021, then retreated by 12.35% to $220000.0 in 2022.
• The last three Revenue figures came in at $220000.0 (Q3 2022), $235000.0 (Q2 2022), and $250000.0 (Q1 2022), per Business Quant data.